Last reviewed · How we verify
Olopatadine 0.1%
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the eye.
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the eye. Used for Allergic conjunctivitis, Itching associated with allergic conjunctivitis.
At a glance
| Generic name | Olopatadine 0.1% |
|---|---|
| Also known as | Patanol |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Selective H1-receptor antagonist and mast cell stabilizer |
| Target | H1 receptor; mast cell stabilization |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology/Allergy |
| Phase | FDA-approved |
Mechanism of action
Olopatadine works through dual action: it blocks histamine H1 receptors on ocular tissues to prevent histamine-mediated allergic responses, and it stabilizes mast cells to reduce the release of inflammatory mediators. This combination provides rapid symptom relief and sustained control of allergic conjunctivitis symptoms including itching, redness, and tearing.
Approved indications
- Allergic conjunctivitis
- Itching associated with allergic conjunctivitis
Common side effects
- Headache
- Ocular irritation
- Blurred vision
- Dry eye
- Keratitis
Key clinical trials
- Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis (PHASE4)
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects (PHASE3)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
- Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan (PHASE4)
- Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |